美国较新的肺高压协会登记研究(Pulmonary Hypertension Association Registry)纳入了2015年至2020年的患者,观察到总体死亡率在1年、2年和3年时分别为8%、16%和21%。即便如此,不同风险类别间的差异仍然很大:低风险患者的结局明显优于中风险或高风险患者。
此外,这些数据也早于一些较新治疗方法的常规应用,包括针对激活素/BMP的新治疗通路,因此不能直接套用于今天确诊的个人。
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237.
Kovacs G, Zeder K, Humbert M, et al. European Respiratory Society clinical practice guidelines update for the treatment of pulmonary arterial hypertension. European Respiratory Journal. 2026;2601178. doi:10.1183/13993003.01178-2026.
Dardi F, Boucly A, Benza R, et al. Risk stratification and treatment goals in pulmonary arterial hypertension. European Respiratory Journal. 2024;64(4):2401323. doi:10.1183/13993003.01323-2024.
Hoeper MM, Pausch C, Olsson KM, et al. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. European Respiratory Journal. 2022;60(1):2102311. doi:10.1183/13993003.02311-2021.
Benza RL, Kanwar MK, Raina A, et al. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. Chest. 2021;159(1):337-346. doi:10.1016/j.chest.2020.08.2069.
Chang KY, Duval S, Badesch DB, et al. Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. Journal of the American Heart Association. 2022;11(9):e024969. doi:10.1161/JAHA.121.024969.
Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448-456. doi:10.1378/chest.11-1460.
Farber HW, Miller DP, Poms AD, et al. Five-Year Outcomes of Patients Enrolled in the REVEAL Registry. Chest. 2015;148(4):1043-1054. doi:10.1378/chest.15-0300.
Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension. European Respiratory Journal. 2024;64(4):2401325. doi:10.1183/13993003.01325-2024.
Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine. 2023;388(16):1478-1490. doi:10.1056/NEJMoa2213558.
Savale L, Benazzo A, Corris P, et al. Transplantation, bridging, and support technologies in pulmonary hypertension. European Respiratory Journal. 2024;64(4):2401193. doi:10.1183/13993003.01193-2024.